drugset / Trial / NCT04921345
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Timeline
- Start
- 2021-06-24
- Primary completion
- 2025-04-28
- Completion
- 2025-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Subject | Nemolizumab | Monoclonal antibody | 10 mg | Subcutaneous |
| Subject | Nemolizumab | Monoclonal antibody | 15 mg | Subcutaneous |
| Subject | Nemolizumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Nemolizumab | Monoclonal antibody | 30 mg | Subcutaneous |